Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its ...
GlobalData on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...
An early view of the immune response to bacteria in the lungs provides clues as to why some people keep TB in check, while ...
In the event of a severe heart attack, immature immune cells are released into the bloodstream from the bone marrow. A ...
A quarter of the global population is estimated to have been infected with Mycobacterium tuberculosis, yet only 5%–10% of those infected go on to develop active tuberculosis (TB). "The big question ...
High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, ...
ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
Flow cytometry continues to evolve, yet many experiments are still limited by avoidable issues in panel design, control selection, reagent handling, and instrument understanding. As analytical ...
A large body of research publications covering hematological disorders, such as acute myeloid leukemia (AML) and multiple ...
Framed in his office, Eric Olson displays what he calls a “unique piece of history.” It’s a letter informing him of a $44 million settlement in a class action lawsuit involving Theranos, the infamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results